![8-Bromoimidazo[1,2-a]pyridine structure](https://ossimg.kuujia.com/scimg/850500/850349-02-9x500.png)
2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| AstaTech | 54834-1/G |
8-BROMOIMIDAZO[1,2-A]PYRIDINE |
850349-02-9 | 97% | 1g |
$63 | 2023-09-17 | |
| AstaTech | 54834-5/G |
8-BROMOIMIDAZO[1,2-A]PYRIDINE |
850349-02-9 | 97% | 5g |
$229 | 2023-09-17 | |
| AstaTech | 54834-25/G |
8-BROMOIMIDAZO[1,2-A]PYRIDINE |
850349-02-9 | 97% | 25g |
$838 | 2023-09-17 | |
| Fluorochem | 077032-5g |
8-Bromoimidazo[1,2-a]pyridine |
850349-02-9 | 98% | 5g |
￡153.00 | 2022-03-01 | |
| Fluorochem | 077032-10g |
8-Bromoimidazo[1,2-a]pyridine |
850349-02-9 | 98% | 10g |
￡282.00 | 2022-03-01 | |
| Fluorochem | 077032-25g |
8-Bromoimidazo[1,2-a]pyridine |
850349-02-9 | 98% | 25g |
￡541.00 | 2022-03-01 | |
| TRC | B684493-100mg |
8-Bromo-imidazo[1,2-a]pyridine |
850349-02-9 | 100mg |
$ 64.00 | 2023-04-18 | ||
| TRC | B684493-250mg |
8-Bromo-imidazo[1,2-a]pyridine |
850349-02-9 | 250mg |
$ 75.00 | 2023-04-18 | ||
| TRC | B684493-500mg |
8-Bromo-imidazo[1,2-a]pyridine |
850349-02-9 | 500mg |
$ 87.00 | 2023-04-18 | ||
| TRC | B684493-1g |
8-Bromo-imidazo[1,2-a]pyridine |
850349-02-9 | 1g |
$ 98.00 | 2023-04-18 |
Audited Supplier
8-Bromoimidazo[1,2-a]pyridine (CAS No. 850349-02-9) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of imidazopyridines, which are known for their diverse biological activities and potential therapeutic applications. The presence of a bromine atom at the 8-position imparts unique chemical and biological properties, making it a valuable scaffold for the development of novel drugs.
The structure of 8-Bromoimidazo[1,2-a]pyridine consists of a fused ring system comprising an imidazole and a pyridine ring. The bromine substituent at the 8-position not only enhances the compound's reactivity but also influences its pharmacokinetic and pharmacodynamic properties. This makes it an attractive candidate for various medicinal applications, including the modulation of receptor activity and enzyme inhibition.
Recent studies have highlighted the potential of 8-Bromoimidazo[1,2-a]pyridine in several therapeutic areas. For instance, research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent anti-inflammatory and analgesic properties. These findings suggest that 8-Bromoimidazo[1,2-a]pyridine could be a promising lead compound for the development of new treatments for inflammatory diseases and pain management.
In addition to its anti-inflammatory effects, 8-Bromoimidazo[1,2-a]pyridine has been investigated for its potential as an antitumor agent. Studies have demonstrated that certain derivatives can selectively inhibit cancer cell growth by targeting specific signaling pathways involved in cell proliferation and survival. This selective inhibition minimizes toxicity to normal cells, making it a potentially safer alternative to conventional chemotherapy agents.
The synthetic accessibility of 8-Bromoimidazo[1,2-a]pyridine is another factor contributing to its popularity in research. Various synthetic routes have been developed to efficiently produce this compound and its derivatives. One common approach involves the condensation of 2-aminopyridine with an appropriate brominated aldehyde or ketone, followed by cyclization to form the imidazopyridine core. This synthetic flexibility allows researchers to easily modify the structure to optimize its biological activity and pharmacological properties.
The physicochemical properties of 8-Bromoimidazo[1,2-a]pyridine, such as solubility and stability, are also important considerations in drug development. Research has shown that the bromine substituent can enhance the lipophilicity of the molecule, which can improve its ability to cross biological membranes and reach target sites within cells. However, careful optimization is required to balance lipophilicity with other factors such as metabolic stability and bioavailability.
In preclinical studies, 8-Bromoimidazo[1,2-a]pyridine has demonstrated favorable pharmacokinetic profiles. It exhibits good oral bioavailability and a suitable half-life, which are crucial for effective drug delivery. Furthermore, its low toxicity profile in animal models suggests that it may be well-tolerated in humans, making it a promising candidate for further clinical evaluation.
The potential applications of 8-Bromoimidazo[1,2-a]pyridine extend beyond traditional pharmaceuticals. In the field of chemical biology, this compound has been used as a tool to probe cellular processes and signaling pathways. Its ability to selectively modulate specific targets provides valuable insights into disease mechanisms and can aid in the identification of new therapeutic targets.
In conclusion, 8-Bromoimidazo[1,2-a]pyridine (CAS No. 850349-02-9) is a multifaceted compound with significant potential in various areas of medicinal chemistry and pharmaceutical research. Its unique structure and biological properties make it an attractive scaffold for the development of novel drugs with diverse therapeutic applications. Ongoing research continues to uncover new possibilities for this compound, further solidifying its importance in modern drug discovery efforts.
